AAAAAA

   
Results: 1-13 |
Results: 13
Immune evasion by muscle-specific gene expression in dystrophic muscle
Authors: Hartigan-O'Connor, D Kirk, CJ Crawford, R Mule, JJ Chamberlain, JS
Citation: D. Hartigan-o'Connor et al., Immune evasion by muscle-specific gene expression in dystrophic muscle, MOL THER, 4(6), 2001, pp. 525-533
How much help does a vaccine-induced T-cell response need?
Authors: Weber, JS Mule, JJ
Citation: Js. Weber et Jj. Mule, How much help does a vaccine-induced T-cell response need?, J CLIN INV, 107(5), 2001, pp. 553-554
Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis
Authors: Morita, Y Yang, JM Gupta, R Shimizu, K Shelden, EA Endres, J Mule, JJ McDonagh, KT Fox, DA
Citation: Y. Morita et al., Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis, J CLIN INV, 107(10), 2001, pp. 1275-1284
Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein
Authors: Shimizu, K Thomas, EK Giedlin, M Mule, JJ
Citation: K. Shimizu et al., Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein, CANCER RES, 61(6), 2001, pp. 2618-2624
T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: Augmentation of dendritic cell-based immunotherapy
Authors: Kirk, CJ Hartigan-O'Connor, D Nickoloff, BJ Chamberlain, JS Giedlin, M Aukerman, L Mule, JJ
Citation: Cj. Kirk et al., T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: Augmentation of dendritic cell-based immunotherapy, CANCER RES, 61(5), 2001, pp. 2062-2070
Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression
Authors: Geiger, JD Hutchinson, RJ Hohenkirk, LF McKenna, EA Yanik, GA Levine, JE Chang, AE Braun, TM Mule, JJ
Citation: Jd. Geiger et al., Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression, CANCER RES, 61(23), 2001, pp. 8513-8519
Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization
Authors: Kotera, Y Shimizu, K Mule, JJ
Citation: Y. Kotera et al., Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization, CANCER RES, 61(22), 2001, pp. 8105-8109
Local administration of dendritic cells inhibits established breast tumor growth: Implications for apoptosis-inducing agents
Authors: Candido, KA Shimizu, K McLaughlin, JC Kunkel, R Fuller, JA Redman, BG Thomas, EK Nickoloff, BJ Mule, JJ
Citation: Ka. Candido et al., Local administration of dendritic cells inhibits established breast tumor growth: Implications for apoptosis-inducing agents, CANCER RES, 61(1), 2001, pp. 228-236
Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2
Authors: Shimizu, K Fields, RC Redman, BG Giedlin, M Mule, JJ
Citation: K. Shimizu et al., Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2, CA J SCI AM, 6, 2000, pp. S67-S75
Gene-modified dendritic cells for use in tumor vaccines
Authors: Kirk, CJ Mule, JJ
Citation: Cj. Kirk et Jj. Mule, Gene-modified dendritic cells for use in tumor vaccines, HUM GENE TH, 11(6), 2000, pp. 797-806
Dendritic cells: at the clinical crossroads
Authors: Mule, JJ
Citation: Jj. Mule, Dendritic cells: at the clinical crossroads, J CLIN INV, 105(6), 2000, pp. 707-708
Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen
Authors: Xie, YC Hwang, C Overwijk, W Zeng, Z Eng, MH Mule, JJ Imperiale, MJ Restifo, NP Sanda, MG
Citation: Yc. Xie et al., Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen, J NAT CANC, 91(2), 1999, pp. 169-175
Systemic administration of interleukin 2 enhances the therapeutic efficacyof dendritic cell-based tumor vaccines
Authors: Shimizu, K Fields, RC Giedlin, M Mule, JJ
Citation: K. Shimizu et al., Systemic administration of interleukin 2 enhances the therapeutic efficacyof dendritic cell-based tumor vaccines, P NAS US, 96(5), 1999, pp. 2268-2273
Risultati: 1-13 |